Results 261 to 270 of about 8,460,931 (324)

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.
Madison M. Reeves   +21 more
wiley   +1 more source

Depression preceding and following the diagnosis of Parkinson's disease and Lewy body dementia. [PDF]

open access: yesGen Psychiatr
Rohde C   +4 more
europepmc   +1 more source

Brain‐derived plasma p‐tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change

open access: yesAlzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Plasma phosphorylated tau (p‐tau), particularly p‐tau217, is a highly specific biomarker of Alzheimer's disease (AD) pathology. However, plasma p‐tau217 can be elevated in rare non‐AD conditions. Brain‐derived (BD) p‐tau217 may reduce these off‐target effects, but its performance against neuropathology has not been evaluated ...
Marisa N. Denkinger   +15 more
wiley   +1 more source

Tau‐associated neuronal loss in the intermediate nucleus of the human hypothalamus, a putative VLPO analog, in progressive supranuclear palsy and Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract BACKGROUND Sleep phenotypes differ in progressive supranuclear palsy (PSP) and Alzheimer's disease (AD). The human intermediate nucleus (IntN), a putative ventrolateral preoptic analog, promotes non‐rapid eye movement (NREM) sleep, but its disease‐specific vulnerability is unclear. METHODS Post mortem hypothalami (n = 30; baseline [Braak stage
Shima Rastegar‐Pouyani   +14 more
wiley   +1 more source

Distinct ocular microvascular alterations in Alzheimer's disease and cerebral small vessel disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION While both Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) involve vascular dysfunction, the ocular microvascular differences between them remain largely underinvestigated. METHODS This cross‐sectional study included 650 participants (149 AD, 276 CSVD, and 225 cognitively unimpaired individuals).
Ziyi Zhang   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy